Medical Condition News

RSS

Scientists reveal structure of cellular protein degradation machinery

Defective proteins that are not disposed of by the body can cause diseases such as Alzheimer's or Parkinson's. Scientists at the Max Planck Institute (MPI) of Biochemistry recently succeeded in revealing the structure of the cellular protein degradation machinery (26S proteasome) by combining different methods of structural biology.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Possible link between vascular lesions and Alzheimer's disease

Approximately 20 percent of all stroke survivors will develop cognitive problems later in life, including vascular dementia. Experts with the Methodist Neurological Institute in Houston say recent research showing a possible link between vascular lesions and Alzheimer's disease is yet another reason to be more vigilant in our efforts to prevent a stroke.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

PLC Systems initiates enrollment in RenalGuard pivotal trial for CIN

PLC Systems Inc., a company focused on innovative medical device technologies, announced the successful enrollment of the first patient in the CIN-RG trial, the company's pivotal trial to study the efficacy of its RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

24 Jan 2012

Novel method can rapidly scan and capture 3D maps of muscle structure

Simon Fraser University associate professor James Wakeling is adding to the arsenal of increasingly sophisticated medical imaging tools with a new signal-processing method for viewing muscle activation details that have never been seen before.

23 Jan 2012

UCSF-led study to sequence DNA from 4,000 people with epilepsy

To probe the genetic secrets of one of the most common neurological diseases, more than 4,000 people with various forms of epilepsy will have their DNA decoded over the next five years in a study led by researchers at the University of California, San Francisco (UCSF) and several collaborating institutions.

23 Jan 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012

The costs of cancer care

But an economic drama that neither [political party] wants to confront is playing itself out in cancer wards and oncologists' offices across the country.

23 Jan 2012

FzioMed's DYNAVISC adhesion barrier gel receives European CE Mark approval

FzioMed, Inc. is pleased to announce that it has received CE Mark approval to market DYNAVISC adhesion barrier gel in Europe for tendon and peripheral nerve surgery.

23 Jan 2012

Haymarket Media launches ChemotherapyAdvisor.com

Haymarket Media Inc., publisher of Monthly Prescribing Reference (MPR), MPR Hematology/Oncology Edition, and Oncology Nurse Advisor (ONA), is pleased to announce the launch of ChemotherapyAdvisor.com, offering oncologists and their support teams a unique clinical decision support tool.

23 Jan 2012

Crux receives CE mark approval for inferior vena cava filter with BDR

Crux Biomedical announced it has received CE mark approval for their revolutionary inferior vena cava filter (IVCF) with bi-directional retrieval (BDR). Vena cava filters are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). Each year in the United States, approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur.

23 Jan 2012

New Penumbra 3D device may effectively treat stroke

At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.

23 Jan 2012

Potential role of omega-3 fatty acid in preventing psychological consequences of accidents

A report in the 5th 2011 issue of Psychotherapy and Psychosomatics suggests the potential role of omega-3 fatty acid in preventing the psychological consequences of an accident.

23 Jan 2012

Study provides valuable information on which cancer patients might need help to quit smoking

A new analysis has found that a substantial number of lung and colorectal cancer patients continue to smoke after being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study provides valuable information on which cancer patients might need help to quit smoking.

23 Jan 2012

Luteolin interferes with cell signaling in colon cancer cells

Luteolin is a flavonoid commonly found in fruit and vegetables. This compound has been shown in laboratory conditions to have anti-inflammatory, anti-oxidant and anti-cancer properties but results from epidemiological studies have been less certain. New research published in BioMed Central's open access journal BMC Gastroenterology shows that luteolin is able to inhibit the activity of cell signaling pathways (IGF and PI3K) important for the growth of cancer in colon cancer cells.

23 Jan 2012

Researchers discover new mechanism that regulates blood pressure

Analyzing all the genes of dozens of people suffering from a rare form of hypertension, Yale University researchers have discovered a new mechanism that regulates the blood pressure of all humans.

23 Jan 2012

Scientists use metabolomics to discover DMS linked with neuropathic pain

Millions of people worldwide suffer from a type of chronic pain called neuropathic pain, which is triggered by nerve damage. Precisely how this pain persists has been a mystery, and current treatments are largely ineffective. But a team led by scientists from The Scripps Research Institute, using a new approach known as metabolomics, has now discovered a major clue: dimethylsphingosine (DMS), a small-molecule byproduct of cellular membranes in the nervous system.

23 Jan 2012

Study describes new pharmacological resistance to colon cancer

Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR.

23 Jan 2012